Skip to main content
. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501

Table 2.

Univariable analysis on survival outcomes of absolute cell counts and immune-inflammatory indices baseline and early Δ, and baseline clinical parameters.

Inflammatory indices ROC-based cut-off values PFS OS
mPFS(95% CI) Univariable(HR; 95% CI; p value) mOS(95% CI) Univariable(HR; 95% CI; p value
Absolute cell counts
Baseline Neutrophils
(x10e3/L)
≥ 4330 6.9
(5.1-10.9)
1.25; 0.99-1.56; p = 0.059 19.4
(12.6-26.4)
1.87; 1.40-2.49; p < 0.001
< 4330 10.2
(8.4-14.3)
1.00 (ref) NR 1.00 (ref)
Early Δ Neutrophils ≥ 730 6.1
(4.7-9.2)
1.29; 1.02-1.62; p = 0.033 20.8
(17.4-43.9)
1.34; 1.01-1.80; p = 0.046
< 730 11.0
(9.3-13.9)
1.00 (ref) 46.9
(25.7-NR)
1.00 (ref)
Baseline Lymphocytes
(x10e3/L)
< 1460 6.4
(5.0-8.4)
1.57; 1.25-1.98; p < 0.001 20.0
(17.1-27.7)
1.88; 1.39-2.53; p < 0.001
≥ 1460 13.9
(9.9-18.5)
1.00 (ref) NR 1.00 (ref)
Early Δ Lymphocytes ≥ -10 8.4
(5.5-12.1)
1.10; 0.88-1.38; p = 0.41 25.7
(20.1-43.9)
1.15; 0.86-1.54; p = 0.34
< -10 9.9
(8.1-12.5)
1.00 (ref) 46.9
(23.0-NR)
1.00 (ref)
Baseline Platelets
(x10e9/L)
≥ 263 8.4
(5.1-10.1)
1.40; 1.11-1.76; p = 0.004 19.4
(13.8-25.7)
1.92; 1.44-2.56; p < 0.001
< 263 10.9
(7.8-15.0)
1.00 (ref) NR 1.00 (ref)
Early Δ Platelets ≥ 17 8.5
(5.5-10.5)
1.07; 0.85-1.34; p = 0.56 26.4
(20.2-NR)
0.97; 0.73-1.30; p = 0.86
< 17 10.8
(8.0-14.3)
1.00 (ref) 34.3
(20.8-NR)
1.00 (ref)
Indices
Baseline NLR ≥ 3.2 5.8
(4.6-8.3)
1.58; 1.26-1.99; p < 0.001 18.7
(11.3-22.7)
2.10; 1.57-2.80; p < 0.001
< 3.2 11.2
(9.5-16.6)
1.00 (ref) NR 1.00 (ref)
Early Δ NLR ≥ 0.5 6.4
(5.0-9.3)
1.37; 1.09-1.72; p = 0.007 21.7
(18.4-43.9)
1.32; 0.99-1.76; p = 0.062
< 0.5 12.1
(9.5-16.8)
1.00 (ref) 46.9
(25.7-NR)
1.00 (ref)
Baseline SII ≥ 720 6.1
(4.7-9.4)
1.51; 1.21-1.90; p < 0.001 18.7
(13.8-22.0)
2.27; 1.69-3.04; p < 0.001
< 720 11.3
(9.5-18.3)
1.00 (ref) NR 1.00 (ref)
Early Δ SII ≥ 218 6.4
(4.6-9.5)
1.24; 0.99-1.57; p = 0.061 24.5
(18.7-NR)
1.22; 0.91-1.64; p = 0.18
< 218 11.0
(9.2-14.7)
1.00 (ref) 30.7
(23.7-NR)
1.00 (ref)
Baseline PLR ≥ 176 6.5
(4.7-9.5)
1.52; 1.21-1.91; p < 0.001 19.9
(15.5-22.7)
2.23; 1.66-3.01; p < 0.001
< 176 11.5
(9.3-16.8)
1.00 (ref) NR 1.00 (ref)
Early Δ PLR ≥ 21 9.2
(5.9-11.3)
1.07; 0.85-1.35; p = 0.54 27.7
(19.4-NR)
1.09; 0.82-1.45; p = 0.57
< 21 9.9
(6.9-14.3)
1.00 (ref) 30.1
(21.7-NR)
1.00 (ref)
Baseline clinical parameter
Heng score Favorable 22.5
(16.4-35.2)
1.00 (ref) NR 1.00 (ref)
Intermediate 8.2
(5.9-9.5)
1.85; 1.36-2.51; p < 0.001 25.7
(20.1-34.3)
2.83; 1.79-4.50; p < 0.001
Poor 2.9
(2.2-5.5)
3.28; 2.16-4.99; p < 0.001 8.1
(3.7-10.7)
7.13; 4.12-12.37; p < 0.001
Metastatic at diagnosis Yes 6.4
(5.3-9.3)
1.21; 0.96-1.53; p = 0.11 21.7
(17.5-34.3)
1.40; 1.05-1.87; p = 0.023
No 11.2
(9.3-14.7)
1.00 (ref) 46.9
(24.8-NR)
1.00 (ref)
Nephrectomy Yes 9.9
(8.3-12.5)
0.60; 0.42-0.85; p = 0.004 43.9
(25.7-NR)
0.43; 0.29-0.62; p < 0.001
No 4.0
(2.9-8.8)
1.00 (ref) 14.5
(8.6-19.4)
1.00 (ref)
Histologic subtype Clear-cell 9.5
(7.9-11.5)
0.95; 0.69-1.31; p = 0.77 29.5
(22.0-NR)
1.08; 0.71-1.63; p = 0.72
Non-clear cell 6.6
(5.0-13.6)
1.00 (ref) NR 1.00 (ref)
Lymph node metastases Yes 7.4
(5.6-10.1)
1.15; 0.92-1.45; p = 0.22 25.7
(19.9-30.7)
1.28; 0.95-1.71; p = 0.10
No 11.0
(8.8-13.8)
1.00 (ref) 46.9
(22.7-NR)
1.00 (ref)
Viscera metastases Yes 9.3
(6.9-11.1)
1.09; 0.72-1.64; p = 0.69 29.8
(22.0-NR)
1.04; 0.62-1.74; p = 0.88
No 11.3
(5.8-23.4)
1.00 (ref) 25.7
(16.7-NR)
1.00 (ref)
Bone metastases Yes 6.4
(4.6-8.4)
1.51; 1.20-1.91; p = 0.001 18.7
(13.1-25.0)
1.81; 1.36-2.42; p < 0.001
No 11.3
(9.3-16.0)
1.00 (ref) 46.9
(29.8-NR)
1.00 (ref)
Line of therapy 2 9.5
(6.6-12.1)
1.00 (ref) 30.1
(21.4-NR)
1.00 (ref)
3 9.5
(6.1-13.1)
1.06; 0.84-1.35; p = 0.61 NR 0.97; 0.71-1.31; p = 0.83
>4 8.3
(3.2-16.6)
0.94; 0.68-1.28; p = 0.68 18.1
(9.3-NR)
0.86; 0.57-1.30; p = 0.48

Early Δ value variations between second and first therapy infusion, mOS median overall survival, mPFS median progression-free survival, NLR neutrophils-to-lymphocytes ratio, NR not reached, PLR platelets-to-lymphocytes ratio, ROC receiving operating curve, SII systemic immune-inflammatory index.

In bold, significant p-values.